Clinical trials

Clinical trial intelligence

Per-cancer measures of registered clinical research: activity, growth, enrollment, who sponsors it and where it runs, how often it stops, and how it compares with the disease burden. Every figure is computed from ClinicalTrials.gov records with a versioned formula; nothing here is an observation.

Entities at this level overlap (a subtype and its parent both count the same study), so column totals are not shown. The 150 entities with the most active studies are listed; use the API (/api/v1/trials/intelligence?level=all) or the CSV export for the full set.

clinicaltrialsComputed150 entities · sorted by Active (desc) · click a header to sort

Cancer	Total	Active	Recruiting	Ph III active / recruiting	Growth YoY	Avg enrollment	Industry share	Sponsor HHI · top sponsor	Countries · US share	Termination share	Trials / 1,000 deaths
Malignant Neoplasm	72,294	20,102	10,885	2,495 / 1,276	+13.3%	488	20%	0.005M.D. Anderson Cancer Center	120 · 43%	29.5%	—
Carcinoma	21,059	7,356	3,959	1,079 / 534	+10.4%	364	25%	0.006National Cancer Institute (NCI)	96 · 45%	35.2%	—
Secondary Malignant Neoplasm	12,016	4,270	2,317	544 / 269	+14%	242	22%	0.007

Computedformula ci-trial-intel-v1· interventional studies only · aggregation over NCIt descendants (depth ≤ 12)· active = RECRUITING, NOT_YET_RECRUITING, ENROLLING_BY_INVITATION, ACTIVE_NOT_RECRUITING

Thresholds: growth requires ≥ 20 studies in the prior window (windows 2025-09-29 → 2026-09-29 vs 2024-09-29 → 2025-09-29); sponsor HHI requires ≥ 10 active studies; termination share requires ≥ 30 terminal studies first posted since 2010-01-01; burden ratios require ≥ 100 annual deaths (USA, latest year with both counts from one source: cdc-uscs). A multinational study contributes to every country it lists, so country shares can sum above 100%. Methodology

Data updated 16 hours agoSource updated unknowncomputed by CancerIndex from ClinicalTrials.gov records